Scientific Organizing Committee: John De Vos, Annelise Bennaceur-Griscelli, Cécile Martinat, François Hirsch and Armelle Regnault
ESC / iPS Similitudes and differences |
||
| 10h00-10h30 | Reprogramming human and non-human primate embryonic stem cells to ground state pluripotency - Pierre Savatier (SBRI, Lyon) | |
| 10h30-11h00 | X-chromosome inactivation in human pluripotent stem cells - Claire Rougeulle (Institut Epignétique, Paris) | |
| 11h00-11h30 | iPSC and Ageing - Jean-Marc Lemaitre (IGF, Montpellier) | |
| 11h30-12h00 | Lymphopoiesis modeling from hES cells - Rima Haddad (Inserm U967, U. Paris Sud, Fontenay aux Roses) | |
| 12h00-12h30 | Christine Baldeschi (Nice) | |
| 12h30 - 14h | Lunch | |
National iPSC Infrastructure |
||
| 14h-14h30 | INGESTEM Large scale ipSC and International pluripotent stem cell Initiatives - Annelise Bennaceur (AP-HP, Inserm) | |
Production of iPS |
||
| 14h30-14h50 | Critical issues to produce GMP iPS cells - John De Vos (IRB, Montpellier) | |
| 14h50-15h10 | CRISPR: genome engineering made easy - Olivier Féraud (ESTeam, Paris) | |
| 15h10-15h30 | Bioprocessing of human pluripotent stem cells - Yacine Laabi (I Stem) | |
Ethical, legislative and regulatory situation |
||
| 15h30-16h00 | Ethics - Laure Coulombel (Agence de la Biomédecine) | |
| 16h00-16h30 | EU support to stem cell research - Charles Kessler (Principal Scientific Officer, DGRI, European Commission) | |
| 16h30-17h00 | Coffee break | |
Stem cells & Biomaterials |
||
| 17h00-17h30 | 3D scaffolds for stem cells in vitro and in vivo - Didier Letourneur (LVTS, Paris) | |
| 17h30-18h00 | Hematopoietic stem cell differentiation into platelet-producing megakaryocytes - Dominique Baruch (Inserm, Paris) | |
iPS for drug screening |
||
| 18h00-18h30 | Screening for neurogenesis modifiers using PSC-derived neuronal progenitors - Alexandra Benchoua (CECS/Istem, Evry) | |
| 18h30-19h00 | Development of highly selective SMN2 splicing modifiers to find a therapy for spinal muscular atrophy - Friedrich Metzer (Roche Innovation Center, Basel) | |
| 20h | Dinner | |
iPS as diseases and gene therapy models |
|
| 9h00-9h30 | Myeloproliferative disorders - Ali Turhan (Inserm, Le Kremlin Bicêtre) |
| 9h30-10h00 | Lentiviral globin gene transfer in beta-thalassemia iPS cell model - Leila Maouche-Chrétien (Inserm, Fontenay-aux-Roses) |
| 10h00-10h30 | Proof of concept for gene therapy in iPSC-derived retinal pigment epithelium from patients - Viki Kalatzis (INM, Montpellier) |
| 10h30-11h00 | Use of human pluripotent stem cells for neuromuscular diseases - Cécile Martinat (Istem, Evry) |
| 11h-11h20 | Coffee break |
| 11h20-11h50 | iPS to model neurodegenerative disorders - Delphine Bohl (ICM, Paris) |
| 11h50-12h20 | iPSC as a cellular model for epithelial physiopathology - Daniel Aberdam (Inserm, St Louis) |
| 12h20-12h50 | When neurodevelopment meets neurodegeneration: patient iPSC derived neurons to study a rare disorder - Matthias Groszer (Inserm) |
| 12h50-14h00 | Lunch |
iPS use (autologous and allogenic) |
|
| 14h00-14h30 | Red blood cells from stem cells in vitro: perspectives for transfusion medicine - Luc Douay (Saint-Antoine, Paris) |
| 14h30-15h00 | Strategies working towards gene/cell therapy of liver diseases - Anne Dubart-Kupperschmitt (Inserm, Paul Brousse) |
| 15h00-15h30 | Optimized generation of neutrophils and macrophages from iPSC to model Chronic Granulomatous Disease - Marie José Stasia-Pauger (CNRS, UMR 5525, Université J. Fourier, Grenoble) |
| 15h30-16h00 | Coffee break |
| 16h00-16h30 | New type of endodermic stem cells for pancreatic and hepatic regeneration - Frank Griscelli (Inserm, Paris V) |
| 16h30-17h00 | Using human pluripotent stem cells to treat retinal disease - Olivier Goureau (Institut de la vision, Paris) |
The end |
|